Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Every day, people living with cancer come to Stanford for help, hope and healing.
Transforming Cancer Care
Stanford Cancer Initiative is an ambitious program to transform the care experience of every cancer patient treated at Stanford. The Initiative combines the latest research and information management protocols with multi-disciplinary, patient-centered care to improve quality of life and overall health outcomes. Integrating leading-edge research and comprehensive care to dramatically change the prognosis and treatment of cancer.
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
-
Steven Artandi tapped to lead Stanford Cancer Institute
A cancer biologist, Artandi studies the role of telomerase in stem cells and cancer. He replaces outgoing director Beverly Mitchell.
-
Inexpensive testing spurs next of kin to assess their own cancer risk
An online effort coupled with lower costs significantly increased the proportion of cancer patients’ relatives who chose to undergo genetic testing for cancer-associated mutations in Stanford study.
-
‘Liquid biopsy’ predicts lymphoma therapy success within days
Changes in circulating tumor DNA levels quickly predict how patients with diffuse large B cell lymphoma are responding to therapy, according to a Stanford-led study. Currently, patients wait months for the results.
